Hydrogen Breakthrough: New Palladium Nanosheet Tech Could Accelerate Green Energy Revolution

Scientists have developed a cost-effective alternative to platinum for use in hydrogen production, replacing the expensive metal with palladium nanosheets to reduce costs and accelerate the shift to clean energy.

As global temperatures surpass the preindustrial benchmark outlined in the 2015 Paris Climate Agreement, the need for large-scale hydrogen production has become more urgent to accelerate the transition to zero-emission alternatives. However, the widespread adoption of hydrogen technology has been hindered by its dependence on costly platinum-based catalysts, making it economically unfeasible for everyday use.

Novel Hydrogen Development

Dr. Hiroaki Maeda and Professor Hiroshi Nishihara of the Tokyo University of Science (TUS) led a team consisting of other researchers from TUS, as well as contributors from Japan Synchrotron Radiation Research Institute, Kyoto Institute of Technology, RIKEN SPring-8 Center, and the National Institute for Materials Science, Japan. The team produced a breakthrough in hydrogen evolution reaction (HER) technology with their bis(diimino)palladium coordination nanosheets (PdDI), nearly duplicating platinum’s efficiency at a significantly lower cost.

Keep reading

Top Auto CEO Says He May Pull Production Out of Mexico If Trump Follows Through on Tariffs

The CEO of Nissan has said he may be forced to move production out of Mexico if Donald Trump imposes tariffs on exports.

The head of the Japanese automaker made the comments during a press conference on Friday.

“From Mexico to the U.S., we are exporting a significant number of cars this fiscal year,” Uchida said, according to Reuters.

”320,000 units are exported from Mexico to the U.S., and if the high tariffs are imposed, we need to be ready for this,” he continued.

”Maybe we can transfer the production of these models elsewhere if this were the decision, we will think how we can make it a reality while monitoring the situation.”

“We are exporting a large volume to U.S., so if there’s a high tariff, this would have huge implications on our business, so we need to monitor this carefully.”

Keep reading

Behavioral and Health Outcomes of mRNA COVID-19 Vaccination: A Case-Control Study in Japanese Small and Medium-Sized Enterprises

Despite ongoing waves of Coronavirus disease 2019 (COVID-19) infections, including significant surges such as the 10th wave, understanding the impact of messenger RNA (mRNA) COVID-19 vaccination on infection risk and associated behavioral changes remains crucial. This study aims to urgently evaluate the effects of mRNA COVID-19 vaccination on COVID-19 infection rates and related behaviors among participants of the Yamato Project, which includes employees of Japanese small and medium-sized enterprises (SMEs).

Methods

A case-control study was conducted using data collected from a survey administered by the Japan Small and Medium Enterprise Management Council in December 2023. Participants included individuals who were part of the Yamato Project, not necessarily limited to SME employees. The survey gathered information on demographic characteristics, COVID-19 infection status, vaccination history, health status before January 2020, and various preventive behaviors. The primary outcome was the presence or absence of COVID-19 infection. Data were analyzed using univariate and multivariate logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for the association between vaccination status and COVID-19 infection.

Results

A total of 913 participants were included in the final analysis. The adjusted ORs for COVID-19 infection among vaccinated individuals compared to unvaccinated individuals were 1.85 (95% CI: 1.33-2.57, p < 0.001). The odds of contracting COVID-19 increased with the number of vaccine doses: one to two doses (OR: 1.63, 95% CI: 1.08-2.46, p = 0.020), three to four doses (OR: 2.04, 95% CI: 1.35-3.08, p = 0.001), and five to seven doses (OR: 2.21, 95% CI: 1.07-4.56, p = 0.033). Behavioral analysis indicated that a reduced frequency of bathing and exercising was significantly associated with higher COVID-19 infection rates (p < 0.05).

Keep reading

Yakuza leader pleads guilty in U.S. court to conspiring to sell nuclear material

A member of the Japanese yakuza criminal underworld pleaded guilty to handling nuclear material sourced from Myanmar and seeking to sell it to fund an illicit arms deal, US authorities said Wednesday.

Yakuza leader Takeshi Ebisawa and co-defendant Somphop Singhasiri had previously been charged in April 2022 with drug trafficking and firearms offenses, and both were remanded.

He was then additionally charged in February 2024 with conspiring to sell weapons-grade nuclear material and lethal narcotics from Myanmar, and to purchase military weaponry on behalf of an armed insurgent group, prosecutors said.

The military weaponry to be part of the arms deal included surface-to-air missiles, the indictment alleged.

“As he admitted in federal court today, Takeshi Ebisawa brazenly trafficked nuclear material, including weapons-grade plutonium, out of Burma,” said Acting US attorney Edward Kim, using another name for Myanmar.

“At the same time, he worked to send massive quantities of heroin and methamphetamine to the United States in exchange for heavy-duty weaponry such as surface-to-air missiles to be used on battlefields in Burma.”

Prosecutors alleged that Ebisawa, 60, “brazenly” moved material containing uranium and weapons-grade plutonium, alongside drugs, from Myanmar.

From 2020, Ebisawa boasted to an undercover officer he had access to large quantities of nuclear materials that he sought to sell, providing photographs of materials alongside Geiger counters registering radiation.

During a sting operation including undercover agents, Thai authorities assisted US investigators in seizing two powdery yellow substances that the defendant described as “yellowcake.”

“The (US) laboratory determined that the isotope composition of the plutonium found in the Nuclear Samples is weapons-grade, meaning that the plutonium, if produced in sufficient quantities, would be suitable for use in a nuclear weapon,” the Justice Department said in its statement at the time.

One of Ebisawa’s co-conspirators claimed they “had available more than 2,000 kilograms (4,400 pounds) of Thorium-232 and more than 100 kilograms of uranium in the compound U3O8 — referring to a compound of uranium commonly found in the uranium concentrate powder known as ‘yellowcake’.”

The indictment claimed Ebisawa had suggested using the proceeds of the sale of nuclear material to fund weapons purchases on behalf of an unnamed ethnic insurgent group in Myanmar.

Keep reading

Following Japan, Europe Set to Approve Exotic New Self-Amplifying RNA ‘Vaccine’ Technology That May ‘Vaccinate’ Others Via Shedding

On Thursday the European Union’s medicine committee recommended marketing authorization of a novel exotic technology referred to as ‘self-amplifying RNA vaccines’ or ‘replicon vaccines’. Called Kostaive, it is reportedly for ‘protection’ against Covid. In October Japan became the first country on earth to begin injecting their population with the new shot.

“On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kostaive, a vaccine intended for the prevention of COVID-19 in adults,” the European Medicines Agency said Thursday.

Unlike the notorious mRNA gene therapy injections used to ‘combat’ Covid, which make the vaccinated individual’s body produce an antigen (the spike protein in the case of the Covid shots) the new saRNA vaccines go a step further, making the body replicate the replication mechanism itself. Traditional (real) vaccines contain the antigen, which is intended to illicit an immune response in the body, unlike mRNA vaccines which make the body itself produce the antigen, which is then intended to illicit an immune response. Traditional vaccines also contain neurotoxins such as aluminum as an adjuvant (to agitate the immune system into action) and mercury as a preservative.

“Kostaive will be available as a powder for dispersion for injection. Kostaive is a RNA-based COVID-19 vaccine (ATC code: J07BN01). It contains a self-amplifying mRNA that encodes the SARS-CoV-2 spike protein. Self-amplifying means that the mRNA also carries instructions to make a protein called replicase. Once administered into a muscle, the replicase protein makes more copies of the mRNA, which the cell can use to make more spike protein. Vaccination with Kostaive induces the production of neutralising antibodies and a cellular immune response targeting the spike protein, which helps protect people against COVID-19,” the European Medicines Agency said Thursday.

The new shot triggers side effects 90 percent of the time.

“During the clinical trials for Kostaive, five deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90 percent of injected participants experienced adverse events, with 74.5 percent reporting systemic reactions and 15.2 percent requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions,” Lifesite News said Tuesday.

The new technology has been labeled as intrinsically dangerous and even as a bioweapon by some, sparking fears of the vaccine itself spreading to the non-vaccinated population, a step far beyond vaccine shedding.

“The man-made genes in the replicon vaccines, if introduced into humans, are likely to spread not only to other humans but also to other species,” The Expose said in September.

The novel vaccine technology is said to spread like a virus, vaccinating even those who refuse to take their shots.

“So this was a way to have a vaccine that spreads like a virus,” talkshow host Mike Adams said in a May 5, 2021 podcast. “And the research on this has been going on for over three decades.”

Keep reading

U.S. Military Bases in South Korea and Japan Arouse Persistent Protests

On August 12, 2024, around 2,500 Okinawans including the island’s governor staged a demonstration near Marine Corps Air Station Futenma.

The main focus of the protest—organized by the anti-U.S. military political party All Okinawa and two civic groups fighting in the courts to eliminate base aircraft noise—was a rash of sexual assaults allegedly committed against local women by U.S. servicemen stationed at the base.

In March, a senior airman, Brennon R.E. Washington was indicted on charges of kidnapping and sexually assaulting a minor. In June, prosecutors indicted Marine Lance Cpl. Jamel Clayton on attempted sexual assault charges.

All Okinawa co-chairman Susumu Inamine, a former mayor of Nago city, told the crowd that the Japanese government had been hiding information regarding these and other cases, and that even Okinawa’s governor was kept in the dark, which, she said, was “unforgivable.” Other speakers at the rally condemned the recent return of Bell Boeing MV-22 Osprey flights over the island, which are known for making a lot of noise.

Keep reading

‘Should Not Be Used in Any Infants’: Higher Death Risk in Beyfortus RSV Shot Clinical Trials

Infants treated for RSV with the monoclonal antibody nirsevimab have significantly higher mortality rates than those treated with a different monoclonal antibody or with a placebo, according to an analysis by the Japanese journal Med Check of three major randomized control trials.

The report reanalyzed clinical trial data showing that nirsevimab — marketed by Sanofi and AstraZeneca as Beyfortus — reduced RSV-associated lower respiratory tract infection and hospitalizations in both high-risk and healthy infants.

However, babies treated with the drug had a higher mortality rate likely linked to adverse effects — including thrombosis (blood clotting) — from the drug itself, the study found.

“Due to the increased mortality, nirsevimab should not be used in any infants,” the study concluded. “Do not use nirsevimab for universal immunization.”

Shortly after its approval by the European Medicines Association in October 2022, and fast-track approval by the U.S. Food and Drug Administration in July 2023, the U.S., France, Spain and Luxembourg launched universal Beyfortus infant immunization campaigns for the 2023-24 RSV season.

Med Check published its appraisal of the clinical trials shortly after France’s National Agency for the Safety of Medicines and Health Products (ANSM) published its first pharmacovigilance data on the drug, compiled during the 2023-24 season.

The ANSM report tracked adverse events related to Beyfortus in France between Sept. 11, 2023, and April 30, 2024. Of 244,495 doses delivered, 198 adverse events were reported to the pharmacovigilance system, of which 153 were considered serious.

The report identified safety signals for stroke, respiratory conditions and hypotonic-hyporesponsive episodes — when an infant suddenly loses muscle strength and becomes “floppy.” Hypotonic-hyporesponsive episodes also are associated with the diphtheria-tetanus-pertussis, or Tdap, vaccine and other vaccines.

There were also three reports of sudden infant death syndrome (SIDS), although researchers said at least one of them was likely not linked to the drug.

The ANSM said each of the signals would be closely monitored in the future, but that a causal link between Beyfortus and those adverse events had not yet been established. The agency concluded the results confirm that the benefits of using the drug to treat bronchiolitis, an RSV infection, outweigh the risks.

The ANSM continues to recommend all newborn babies receive the Beyfortus shot this RSV season.

Keep reading

Top Japanese medics are “Gunning for Gates”

“Japan Warns Bill Gates His “Days Are Numbered” After Abortion Drugs Found in Vaccines Japan has sent a clear message to Bill Gates – his time is running out.

With the government’s Covid Task Force swiftly uncovering his crimes, the walls are closing in on the globalist kingpin. Japanese scientists are now taking a stand, urging international prosecutors to bring a case of crimes against humanity against Gates.

Among them, world-renowned experts like Dr. Fukushima are raising the alarm, revealing shocking discoveries that some vaccines contain abortion drugs designed for depopulation. They warn that there is overwhelming evidence suggesting Gates isn’t finished yet – he has plans to inflict even more harm in the near future. It’s time for the world to unite and bring him to justice!”

Keep reading

Japan Approves World’s First ‘Self-amplifying’ mRNA COVID Shot — Is the U.S. Next?

Japan is offering a self-amplifying mRNA vaccine as one of the five routine COVID-19 vaccines available to the public for the 2024-2025 fall and winter seasons.

Japanese regulators approved the ARCT-154 shot in November 2023. According to a press release, ARCT-154 is the world’s first self-amplifying mRNA COVID-19 vaccine. Japan’s Ministry of Health, Labour and Welfare approved the vaccine for adults. It is jointly produced by the biotechnology firm CSL and Arcturus Therapeutics.

“The approval is based on positive clinical data from several ARCT-154 studies … which achieved higher immunogenicity results and a favorable safety profile compared to a standard mRNA COVID-19 vaccine comparator,” CSL said.

Japan’s vaccination program will offer the vaccines to people 65 and over, and 60- to 64-year-olds with severe underlying conditions, at a maximum cost of 7,000 yen (approximately $47). People not in these two categories can also receive the shots, but the fee will not be capped.

Keep reading